Inventors:
Jeffrey Alan Dodge - Indianapolis IN
Andrew Lawrence Glasebrook - Zionsville IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 31445
US Classification:
514319, 514213, 514331, 514428, 514650, 540585, 540609, 544105, 546192, 546205, 546229, 546233, 548566, 548570, 548571, 548575
Abstract:
A class of substituted benzylnaphthylene compounds of the structure where R and R are independently hydrogen, alkyl of one to six carbon atoms, acyl of two to six carbon atoms, or phenacyl; X is â(CH ) ; Y is absent or is selected from 1,4-piperazinylene; ureido; N-(lower alkyl)ureido; Nâ-(lower alkyl)ureido; or N, Nâ-(di-lower alkyl ureido; and Z is 1-, 2- or 3-pyrrolidinyl; 1-, 2-, or 3-[1-(lower alkyl) pyrrolidinyl]; 1- 2-, 3- or 4-piperidinyl; 1-, 2-, 3- or 4-[1-lower alkyl)piperidinyl]; N,N-dialkyl; 1-azepinyl; 1- or 2-naphthylamino, 4-morpholinyl, dimethyl-4-morpholinyl, 3-azaspiro[5. 5]undecan-3-yl; pyrrolidinon-1-yl; unsubstituted phenyl; or phenyl substituted with acyl of two to four carbon atoms, alkyl of one to four carbon atoms, halo, or alkoxy of one to four carbon atoms; with the proviso that n is not 2 or 3 when Z is 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, N,N-dimethylamino or N,N-diethylamino; are selective estrogen receptor modulators useful in the prophylaxis or treatment of breast cancer.
